-
公开(公告)号:US09665002B2
公开(公告)日:2017-05-30
申请号:US14930869
申请日:2015-11-03
IPC分类号: G03F7/039 , G03F7/004 , G03F7/30 , G03F7/32 , G03F7/38 , G03F7/20 , C07D263/04 , C07D233/02 , C07D277/04 , C07D207/04 , C07D279/12 , C07D295/112 , C07D203/14 , C07D241/04 , C07D225/02 , C07D223/04 , C07D211/06 , C07D205/04 , C07D265/30 , C07D295/155 , C07D213/79 , C07D295/26 , C07C381/12 , G03F7/16 , C07C25/00 , C07C69/78 , C07C69/76 , C07C25/02
CPC分类号: G03F7/0397 , C07C25/00 , C07C25/02 , C07C69/76 , C07C69/78 , C07C381/12 , C07D203/14 , C07D205/04 , C07D207/04 , C07D211/06 , C07D213/79 , C07D223/04 , C07D225/02 , C07D233/02 , C07D241/04 , C07D263/04 , C07D265/30 , C07D277/04 , C07D279/12 , C07D295/112 , C07D295/155 , C07D295/26 , G03F7/0045 , G03F7/0046 , G03F7/11 , G03F7/168 , G03F7/2037 , G03F7/2041 , G03F7/30 , G03F7/322 , G03F7/325 , G03F7/38
摘要: Sulfonium and iodonium salts of a carboxylate having an aromatic ring to which a nitrogen-containing alkyl or cyclic structure is attached are novel. The onium salt functions as an acid diffusion controlling agent in a resist composition, enabling to form a pattern of good profile with high resolution, improved MEF, LWR and DOF.
-
公开(公告)号:US20170121313A1
公开(公告)日:2017-05-04
申请号:US15314106
申请日:2015-05-26
IPC分类号: C07D403/14 , C07D241/04 , C07D403/12 , C07D403/06 , C07D401/06 , C07D401/12 , C07D401/14
CPC分类号: C07D403/14 , C07D241/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12
摘要: The present invention relates to novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.
-
公开(公告)号:US09617231B2
公开(公告)日:2017-04-11
申请号:US14941800
申请日:2015-11-16
申请人: H. Lundbeck A/S
IPC分类号: C07D295/073 , C07B59/00 , C07D241/04 , A61K31/451 , A61K31/454 , A61K31/4545 , A61K31/495 , A61K31/496 , A61K31/519 , A61K31/551 , A61K31/554 , C07C45/61 , C07C45/67
CPC分类号: C07D295/073 , A61K31/451 , A61K31/454 , A61K31/4545 , A61K31/495 , A61K31/496 , A61K31/519 , A61K31/551 , A61K31/554 , C07B59/002 , C07B2200/05 , C07C45/61 , C07C45/67 , C07D241/04
摘要: The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising administration of such compounds.
-
公开(公告)号:US09549983B2
公开(公告)日:2017-01-24
申请号:US14255637
申请日:2014-04-17
IPC分类号: A61K47/18 , A61K31/713 , A61K47/22 , C12N15/113 , A61K9/127 , C12N15/11 , C12N15/88 , C07D233/61 , C07D233/64 , C07D239/42 , C07D241/04 , C07C237/06 , C07D295/03 , C07D211/36 , C07D295/13 , C07D295/15 , C07C211/21 , A61K38/00
CPC分类号: C07D403/06 , A61K9/107 , A61K9/127 , A61K9/1272 , A61K9/145 , A61K9/146 , A61K31/713 , A61K38/00 , A61K47/18 , A61K47/22 , C07C211/21 , C07C237/06 , C07D211/36 , C07D233/61 , C07D233/64 , C07D239/42 , C07D241/04 , C07D243/08 , C07D295/03 , C07D295/13 , C07D295/15 , C07D401/04 , C07D403/04 , C12N15/111 , C12N15/1137 , C12N15/88 , C12N2310/14 , C12N2310/321 , C12N2320/32 , C12Y204/02008
摘要: The present invention relates to lipid compounds and uses thereof. In particular, the compounds include a class of cationic lipids having an amine moiety, such as an amino-amine or an amino-amide moiety. The lipid compounds are useful for in vivo or in vitro delivery of one or more agents (e.g., a polyanionic payload or an antisense payload, such as an RNAi agent).
摘要翻译: 本发明涉及脂质化合物及其用途。 特别地,化合物包括具有胺部分的一类阳离子脂质,例如氨基胺或氨基 - 酰胺部分。 脂质化合物可用于体内或体外递送一种或多种试剂(例如聚阴离子载体或反义载体,例如RNAi试剂)。
-
公开(公告)号:US09522892B2
公开(公告)日:2016-12-20
申请号:US13688442
申请日:2012-11-29
申请人: PEROSPHERE INC.
IPC分类号: A61K31/497 , C07D241/04 , A61K31/122 , A61K31/4965 , C07D295/13
CPC分类号: A61K31/495 , A61K9/0053 , A61K31/122 , A61K31/4965 , C07D241/04 , C07D295/13
摘要: Novel anticoagulant reversal compounds are disclosed, as well as methods of making the compounds, pharmaceutical compositions including the compounds, methods of using the compounds to reverse the anticoagulant effects of coagulation inhibitors, and diagnostic assays comprising the compounds.
摘要翻译: 公开了新的抗凝血剂逆转化合物,以及制备化合物的方法,包括该化合物的药物组合物,使用该化合物来逆转凝血抑制剂的抗凝血作用的方法,以及包含该化合物的诊断测定法。
-
公开(公告)号:US09452980B2
公开(公告)日:2016-09-27
申请号:US12969613
申请日:2010-12-16
IPC分类号: C07D207/09 , C07D207/10 , C07D207/12 , C07D211/26 , C07D241/04 , C07D265/30 , C07D267/08 , C07D295/135 , C07D401/04 , C07D401/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , A61K31/40 , A61K31/495 , A61K31/496 , A61K31/454 , A61K31/553 , A61P25/00 , A61P25/24 , A61P25/18 , A61P25/16 , A61P25/22 , A61K9/20
CPC分类号: C07D207/09 , A61K9/2018 , C07D207/10 , C07D207/12 , C07D211/26 , C07D241/04 , C07D263/32 , C07D265/30 , C07D267/08 , C07D267/10 , C07D295/135 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D495/04
摘要: The invention relates to compounds of formula wherein R, R1, R2, X, and Y are as defined herein and to a pharmaceutically suitable acid addition salt thereof. Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
摘要翻译: 式I化合物对微量胺相关受体(TAAR)具有良好的亲和力,特别是TAAR1。 这些化合物可用于治疗抑郁症,焦虑障碍,双相情感障碍,注意力缺陷多动障碍(ADHD),应激相关疾病,精神病性精神障碍如精神分裂症,神经系统疾病如帕金森病,神经退行性疾病如阿尔茨海默病, 癫痫,偏头痛,高血压,药物滥用和代谢障碍如进食障碍,糖尿病,糖尿病并发症,肥胖症,血脂异常,能量消耗和同化障碍,体温平衡紊乱和失调,睡眠和昼夜节律紊乱以及心血管疾病 。
-
公开(公告)号:US09440966B2
公开(公告)日:2016-09-13
申请号:US14007868
申请日:2012-03-28
IPC分类号: C07D241/04 , A61K31/437 , C07D471/04 , A23L1/29 , A23L1/30 , A61K8/49 , A61K8/69 , A61Q19/06
CPC分类号: C07D471/04 , A23L33/10 , A23L33/30 , A23L33/40 , A23V2002/00 , A61K8/49 , A61K8/4926 , A61K8/494 , A61K8/69 , A61K31/437 , A61K31/444 , A61K31/496 , A61K31/5377 , A61K2800/92 , A61Q19/06 , C07D241/04 , A23V2200/326 , A23V2200/3262 , A23V2200/328
摘要: Present invention refers to new compounds of formula I or II, its synthesis and its use in the treatment of metabolic syndrome, particularly for the treatment of type I or type II diabetes and/or metabolic syndrome or metabolic disease or metabolic disorders.
摘要翻译: 本发明是指式I或II的新化合物,其合成及其在治疗代谢综合征中的用途,特别是用于治疗I型或II型糖尿病和/或代谢综合征或代谢性疾病或代谢障碍。
-
公开(公告)号:US09439968B2
公开(公告)日:2016-09-13
申请号:US14987717
申请日:2016-01-04
发明人: Daniel Griffith Anderson , Kathryn Ann Whitehead , Joseph R. Dorkin , Arturo Jose Vegas , Yunlong Zhang , Robert S. Langer
IPC分类号: A61K47/22 , C07D295/13 , C07D241/04 , C12N15/113
CPC分类号: A61K47/22 , A61K9/1272 , A61K9/5123 , A61K31/225 , A61K31/357 , A61K31/40 , A61K31/445 , A61K31/495 , A61K31/4985 , A61K31/573 , A61K31/704 , A61K31/713 , A61K45/06 , A61K47/18 , A61K47/542 , A61K47/543 , A61K47/6925 , C07C225/06 , C07C229/12 , C07C229/14 , C07C229/24 , C07C229/26 , C07C229/28 , C07C229/34 , C07C2601/14 , C07D207/09 , C07D211/14 , C07D211/26 , C07D211/34 , C07D241/04 , C07D295/13 , C07D295/15 , C07D295/16 , C07D319/16 , C07D319/18 , C07D487/04 , C12N15/111 , C12N15/1137 , C12N15/88 , C12N2310/14 , C12N2320/32 , A61K2300/00
摘要: Provided herein are lipidoids that may be prepared from the conjugate addition of alkylamines to acrylates. In some embodiments, provided lipidoids are biodegradable and may be used in a variety of drug delivery systems. Given the amino moiety of the lipidoids, they are well-suited for the delivery of polynucleotides, in addition to other agents. Nanoparticles containing the inventive lipidoids and polynucleotides have been prepared and have been shown to be effective in delivering siRNA.
-
公开(公告)号:US09382222B2
公开(公告)日:2016-07-05
申请号:US14101566
申请日:2013-12-10
申请人: Genentech, Inc.
发明人: Benjamin Fauber , Olivier Rene , Monique Bodil van Niel , Simon Gaines , Jonathan Killen , Stuart Ward
IPC分类号: C07D241/04 , C07D295/00 , A61K31/497 , C07D295/26 , C07D211/58 , C07D211/96 , C07D295/096 , C07D295/185 , C07D401/12 , C07D211/46 , C07D295/116 , C07D211/62
CPC分类号: C07D295/26 , C07D211/46 , C07D211/58 , C07D211/62 , C07D211/96 , C07D295/096 , C07D295/116 , C07D295/185 , C07D401/12
摘要: Compounds of the formula Ia or Ib: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, A, X1, X2, X3, X4, Y, Z, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
摘要翻译: 式Ia或Ib化合物或其药学上可接受的盐,其中m,n,p,q,r,A,X 1,X 2,X 3,X 4,Y,Z,R 1,R 2,R 3,R 4,R 5,R 6 ,R7和R8如本文所定义。 还公开了制备化合物和使用该化合物治疗炎性疾病如关节炎的方法。
-
公开(公告)号:US20160145195A1
公开(公告)日:2016-05-26
申请号:US14904446
申请日:2014-07-21
IPC分类号: C07C217/46 , C07D207/10 , C09K5/00 , C07D241/04 , C11D7/50 , C07D265/30 , C07D211/38
CPC分类号: C07C217/46 , C07D207/10 , C07D211/38 , C07D223/04 , C07D241/04 , C07D265/30 , C07D279/12 , C09K5/00 , C11D1/004 , C11D7/5018
摘要: Provided are amine-containing hydrofluoroether compounds represented by the following general formula (I), wherein (I) Y is a single bond or CF2 and wherein (i) Rf.1 and Rf2 are independently linear or branched perfluoroalkyl groups having with 1-8 carbon atoms and optionally comprise at least one catenated heteroatom, or (ii) Rf1 and Rf2 are bonded together to form a ring structure having 4-6 carbon atoms and optionally comprise one or more catenated heteroatoms; with the proviso that if Rf1 and Rf2 are bonded together to form a ring structure comprising a nitrogen heteroatom, said nitrogen heteroatom is tertiary and is bonded to a perfluoroalkyl group having 1-3 carbon atoms.
摘要翻译: 提供由以下通式(I)表示的含胺的氢氟醚化合物,其中(I)Y是单键或CF 2,其中(i)Rf 1和Rf 2独立地是具有1-8的直链或支链全氟烷基 碳原子并且任选地包含至少一个链状杂原子,或(ii)Rf1和Rf2键合在一起形成具有4-6个碳原子的环结构,并且任选地包含一个或多个链状杂原子; 条件是如果Rf1和Rf2键合在一起形成包含氮杂原子的环结构,则所述氮杂原子是叔烷基并且与具有1-3个碳原子的全氟烷基键合。
-
-
-
-
-
-
-
-
-